Jump to ContentJump to Main Navigation
Show Summary Details
More options …

Drug Metabolism and Personalized Therapy

Official journal of the European Society of Pharmacogenomics and Personalised Therapy

Editor-in-Chief: Llerena, Adrián

Editorial Board: Benjeddou, Mongi / Chen, Bing / Dahl, Marja-Liisa / Devinsky, Ferdinand / Hirata, Rosario / Hubacek, Jaroslav A. / Ingelman-Sundberg, Magnus / Maitland-van der Zee, Anke-Hilse / Manolopoulos, Vangelis G. / Marc, Janja / Melichar, Bohuslav / Meyer, Urs A. / Nair, Sujit / Nofziger, Charity / Peiro, Ana / Sadee, Wolfgang / Salazar, Luis A. / Simmaco, Maurizio / Turpeinen, Miia / Schaik, Ron / Shin, Jae-Gook / Visvikis-Siest, Sophie / Zanger, Ulrich M.

CiteScore 2018: 1.01

SCImago Journal Rank (SJR) 2018: 0.277
Source Normalized Impact per Paper (SNIP) 2018: 0.446

See all formats and pricing
More options …
Volume 32, Issue 3


Imatinib quantification in human serum with LC-MS3 as an effective way of protein kinase inhibitor analysis in biological matrices

Marek Dziadosz
  • Corresponding author
  • Institute of Legal Medicine, Hannover Medical School (MHH), Carl-Neuberg-Str. 1, 30625 Hannover, Germany, Phone: +495115324558, E-mail:
  • Email
  • Other articles by this author:
  • De Gruyter OnlineGoogle Scholar
/ Michael Klintschar / Jörg Teske
Published Online: 2017-08-08 | DOI: https://doi.org/10.1515/dmpt-2017-0016



As imatinib gained a lot of attention in the field of medicine, appropriate methods are needed for drug analysis. LC-MS/MS combined with complex sample preparation and column enrichment is usually the method of choice when high sensitivity is necessary. The application of LC-MS3 in imatinib quantification has not been discussed in the literature.


An LC-MS3 imatinib quantification method was developed and validated in human serum. The sample preparation was based on the liquid-liquid extraction of 50 μL human serum. Chromatographic separation was performed using a Luna 5 μm C18 (2) 100 A, 150 mm×2 mm column and the elution was done using a mobile phase consisting of A (H2O/methanol=95/5, v/v) and B (H2O/methanol=3/97, v/v), both with 10 mM ammonium acetate and 0.1% acetic acid.


The conditions applied resulted in a limit of detection/quantification value of 0.14/0.45 ng/mL reached without a sophisticated sample preparation technique or enrichment column application. It could be demonstrated that MS3 detection is a very effective way of sensitive imatinib quantification. Further, it could be stated that the strategy presented can be very useful for a sensitive analysis of other protein kinase inhibitors, because their molecule structure is appropriate for MS3 detection.


The presented analytical strategy is an effective way of protein kinase inhibitor analysis in human serum.

Keywords: Gleevec; Glivec; imatinib; liquid chromatography-tandem mass spectrometry; STI-571; tyrosine kinase inhibitor


  • 1.

    Baselt RC. Disposition of toxic drugs and chemicals in men, 9th ed. Seal Beach: Biomedical Publications, 2011.Google Scholar

  • 2.

    Birch M, Morgan PE, Handley S, Ho A, Ireland R, Flanagan RJ. Sample methodology for the therapeutic drug monitoring of the tyrosine kinase inhibitors dasatinib and imatinib. Biomed Chromatogr 2013;27:335–42.PubMedGoogle Scholar

  • 3.

    Caterino M, Casadei GM, Arvonio R, De Francia S, Pirro E, Piccione FM, et al. Quantification of imatinib plasma levels in patients with chronic myeloid leukemia: comparison between HPLC-UV and LC-MS/MS. Int Pept Res Ther 2013;19:109–16.Web of ScienceCrossrefGoogle Scholar

  • 4.

    Miura M, Takahashi N, Sawada K. Quantitative determination of imatinib in human plasma with high-performance liquid chromatography and ultraviolet detection. J Chromatogr Sci 2011;49:412–5.CrossrefPubMedGoogle Scholar

  • 5.

    Dziadosz M, Bartels H. Imatinib quantification in human serum for clinical purposes using high performance liquid chromatography with diode array detector. Acta Chim Slov 2011;58:347–50.PubMedGoogle Scholar

  • 6.

    Velpandian T, Mathur R, Agarwal NK, Arora B, Kumar L, Gupta SK. Development and validation of a simple liquid chromatographic method with ultraviolet detection for the determination of imatinib in biological samples. J Chromatogr B 2004;804:431–4.CrossrefGoogle Scholar

  • 7.

    Widmer N, Béguin A, Rochat B, Buclin T, Kovacsovics T, Duchosal MA, et al. Determination of imatinib (Gleevec®) in human plasma by solid-phase extraction-liquid chromatography-ultraviolet absorbance detection. J Chromatogr B 2004;803:285–92.CrossrefGoogle Scholar

  • 8.

    Guetens G, Prenen H, De Boeck G, van Oosterom A, Schöffski P, Highley M, et al. Simultaneous determination of AMN107 and imatinib (Gleevec®, Glivec®, STI571) in cultured tumour cells using an isocratic high-performance liquid chromatography procedure with UV detection. J Chromatogr B 2007;846:341–5.Web of ScienceCrossrefGoogle Scholar

  • 9.

    Schleyer E, Pursche S, Köhne CH, Schuler U, Renner U, Gschaidmeier H, et al. Liquid chromatographic method for detection and quantification of STI–571 and its main metabolite N-desmethyl-STI in plasma, urine, cerebrospinal fluid, culture medium and cell preparations. J Chromatogr B 2004;799:23–36.CrossrefGoogle Scholar

  • 10.

    Bouchet S, Chauzit E, Ducint D, Castaing N, Canal-Raffin M, Moore N, et al. Simultaneous determination of nine tyrosine kinase inhibitors by 96-well solid-phase extraction and ultra performance LC/MS-MS. Clin Chim Acta 2011;412:1060–7.Web of SciencePubMedCrossrefGoogle Scholar

  • 11.

    Götze L, Hegele A, Metzelder SK, Renz H, Nockher WA. Development and clinical application of a LC-MS/MS method for simultaneous determination of various tyrosine kinase inhibitors in human plasma. Clin Chim Acta 2012;413:143–9.PubMedCrossrefWeb of ScienceGoogle Scholar

  • 12.

    Zhang Y, Qiang S, Yu Z, Zhang W, Xu Z, Yang L, et al. LC-MS/MS determination of imatinib and N-desmethyl imatinib in human plasma. J Chromatogr Sci 2014;52:344–50.CrossrefWeb of ScienceGoogle Scholar

  • 13.

    Moreno JM, Wojnicz A, Steegman JL, Cano-Abad MF, Ruiz-Nuno A. Imatinib assay by high-performance liquid chromatography in tandem mass spectrometry with solid-phase extraction in human serum. Biomed Chromatogr 2013;27:502–8.CrossrefGoogle Scholar

  • 14.

    Klawitter J, Zhang YL, Klawitter J, Anderson N, Serkova NJ, Christians U. Development and validation of a sensitive assay for the quantification of imatinib using LC/LC-MS/MS in human whole blood and cell culture. Biomed Chromatogr 2009;23:1251–8.CrossrefWeb of SciencePubMedGoogle Scholar

  • 15.

    Bakhtiar R, Lohne J, Ramos L, Khemani L, Hayes M, Tse F. High-throughput quantification of the anti-leukemia drug STI571 (Gleevec™) and its main metabolite (CGP 74588) in human plasma using liquid chromatography-tandem mass spectrometry. J Chromatogr B 2002;768:325–40.CrossrefGoogle Scholar

  • 16.

    Andriamanana I, Gana I, Duretz B, Hulin A. Simultaneous analysis of anticancer agents bortezomib, imatinib, nilotinib, dasatinib, erlotinib, lapatinib, sorafenib, sunitinib and vandetanib in human plasma using LC/MS/MS. J Chromatogr B 2013;926: 83–91.CrossrefWeb of ScienceGoogle Scholar

  • 17.

    Dziadosz M, Lessig R, Bartels H. HPLC-DAD protein kinase inhibitor analysis in human serum. J Chromatogr B 2012; 893–894:77–81.Web of ScienceGoogle Scholar

  • 18.

    Dziadosz M, Lessig R, Bartels H. Protein kinase inhibitor analysis with the core-shell separation technique. Anal Bioanal Chem 2012;404:2083–6.PubMedWeb of ScienceCrossrefGoogle Scholar

  • 19.

    Dziadosz M, Wagner MC, Lipka DB, Fischer T, Bartels H. High-performance liquid chromatography with ultraviolet detection and protein precipitation as a way of quantitative determination of nilotinib with and without internal standard. J Liq Chrom Rel Technol 2012;35:2503–10.Google Scholar

  • 20.

    Matuszewski BK, Constanzer ML, Chavez-Eng CM. Strategies for the assessment of matrix effect in quantitative bioanalytical methods based on HPLC-MS/MS. Anal Chem 2003;75:3019–30.CrossrefPubMedGoogle Scholar

About the article

Received: 2017-04-10

Accepted: 2017-07-13

Published Online: 2017-08-08

Published in Print: 2017-09-26

Author contributions: All the authors have accepted responsibility for the entire content of this submitted manuscript and approved submission.

Research funding: None declared.

Employment or leadership: None declared.

Honorarium: None declared.

Competing interests: The funding organization(s) played no role in the study design; in the collection, analysis and interpretation of data; in the writing of the report; or in the decision to submit the report for publication.

Citation Information: Drug Metabolism and Personalized Therapy, Volume 32, Issue 3, Pages 147–150, ISSN (Online) 2363-8915, ISSN (Print) 2363-8907, DOI: https://doi.org/10.1515/dmpt-2017-0016.

Export Citation

©2017 Walter de Gruyter GmbH, Berlin/Boston.Get Permission

Comments (0)

Please log in or register to comment.
Log in